Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14311842 | 0.86 | HSD17B10 (0.39) | HRH4ALDH1A1CYP1A2HRH2TDP1 | |
| SCHEMBL7854955 | 0.78 | — | — | |
| SCHEMBL4957048 | 0.78 | PAOX (0.30) | — | |
| SCHEMBL4103971 | 0.76 | — | — | |
| SCHEMBL4633867 | 0.74 | — | — | |
| SCHEMBL6135863 | 0.70 | ALOX15 (0.35) | CYP1A2 | |
| SCHEMBL3081072 | 0.69 | MAPT (0.35) | HRH4ALDH1A1CYP1A2HRH2TDP1 | |
| SCHEMBL14152524 | 0.68 | ALOX5 (0.39) | TDP1 | |
| SCHEMBL14889676 | 0.66 | ALOX5 (0.43) | — | |
| SCHEMBL203010 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521447-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-21 | — | — | US | claimed |
| EP-1606283-B1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7521447-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039685-A2 | Heterobicyclic compounds as P38 inhibitors | Array Biopharma, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1997810-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997811-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1606283-B1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | HRH4 4002/4885ALDH1A1 4699/4885CYP1A2 4481/4885 |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | HRH4 2933/4885ALDH1A1 2076/4885CYP1A2 3236/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | HRH4 3997/4885ALDH1A1 4642/4885CYP1A2 4401/4885 |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | HRH4 2933/4885ALDH1A1 2076/4885CYP1A2 3236/4885 |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | HRH4 4005/4885ALDH1A1 4699/4885CYP1A2 4462/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | HRH4 3729/4885ALDH1A1 1054/4885CYP1A2 1551/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | HRH4 2637/4885ALDH1A1 2000/4885CYP1A2 2617/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | HRH4 4002/4885ALDH1A1 4699/4885CYP1A2 4481/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | HRH4 4002/4885ALDH1A1 4699/4885CYP1A2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.